Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · IEX Real-Time Price · USD
3.690
+0.150 (4.24%)
Jul 22, 2024, 10:56 AM EDT - Market open
Daré Bioscience Employees
As of December 31, 2023, Daré Bioscience had 26 total employees, including 23 full-time and 3 part-time employees. The number of employees decreased by 4 or -13.33% compared to the previous year.
Employees
26
Change (1Y)
-4
Growth (1Y)
-13.33%
Revenue / Employee
$108,353
Profits / Employee
-$1,110,548
Market Cap
31.01M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
CareCloud | 3,600 |
Rapid Micro Biosystems | 193 |
Evogene | 142 |
Pluri | 134 |
Spectral AI | 78 |
Surrozen | 42 |
Lipocine | 17 |
Akari Therapeutics, | 12 |
DARE News
- 3 days ago - Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule - GlobeNewsWire
- 21 days ago - Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors - Newsfile Corp
- 25 days ago - Daré Bioscience Announces Reverse Stock Split - GlobeNewsWire
- 2 months ago - Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update - GlobeNewsWire
- 2 months ago - Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network - GlobeNewsWire
- 2 months ago - Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts - GlobeNewsWire
- 3 months ago - Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 - GlobeNewsWire
- 3 months ago - Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive - GlobeNewsWire